Matches in SemOpenAlex for { <https://semopenalex.org/work/W192769413> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W192769413 endingPage "613" @default.
- W192769413 startingPage "609" @default.
- W192769413 abstract "Background. Pediatric skin and skin structure infections are often polymicrobial and require empiric therapy effective against pathogens that may be resistant to many antimicrobial agents. The present study tested the efficacy and safety of a parenteral beta-lactam/beta-lactamase inhibitor combination, ampicillin/sulbactam, and a beta-lactamase-stable cephalosporin, cefuroxime, in serious pediatric skin and skin structure infections requiring hospitalization and parenteral antimicrobial therapy. Methods. This was a multicenter, randomized, prospective, comparative open label trial that enrolled patients 3 months through 11 years of age. Patients received 150 to 300 mg/kg/day ampicillin/sulbactam in equally divided intravenous doses every 6 h. Cefuroxime was given in a dosage of 50 to 100 mg/kg/day either intravenously or intramuscularly in equally divided doses every 6 or 8 h. Maximum treatment was not to exceed 14 days. Patients could receive subsequent oral antimicrobial treatment at the investigator's discretion. Results. At final evaluation for clinical efficacy, 78.0% (n = 46) of the 59 evaluable patients who received ampicillin/sulbactam were cured and 22.0% (n = 13) were improved. The respective values for the 39 evaluable patients treated with cefuroxime were 76.9% (n = 30) and 23.1% (n = 9). At the end of treatment all pathogens were eradicated from 93.2% (n = 55) of 59 patients treated with ampicillin/sulbactam and from 100% of 39 who received cefuroxime. There were no significant differences between treatments in clinical or bacteriologic efficacy. Both ampicillin/sulbactam and cefuroxime were well-tolerated. Conclusion. Both ampicillin/sulbactam and cefuroxime provide safe and effective parenteral antibiotic therapy in pediatric patients with serious skin and skin structure infections." @default.
- W192769413 created "2016-06-24" @default.
- W192769413 creator A5041255852 @default.
- W192769413 creator A5052017127 @default.
- W192769413 creator A5057792641 @default.
- W192769413 creator A5082799023 @default.
- W192769413 date "1999-07-01" @default.
- W192769413 modified "2023-09-25" @default.
- W192769413 title "Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients" @default.
- W192769413 cites W1964004587 @default.
- W192769413 cites W1972020615 @default.
- W192769413 cites W1981050914 @default.
- W192769413 cites W2024430469 @default.
- W192769413 cites W2026559683 @default.
- W192769413 cites W2028304474 @default.
- W192769413 cites W2044768822 @default.
- W192769413 cites W2150503785 @default.
- W192769413 cites W3093696874 @default.
- W192769413 cites W56553380 @default.
- W192769413 cites W82057326 @default.
- W192769413 doi "https://doi.org/10.1097/00006454-199907000-00008" @default.
- W192769413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10440436" @default.
- W192769413 hasPublicationYear "1999" @default.
- W192769413 type Work @default.
- W192769413 sameAs 192769413 @default.
- W192769413 citedByCount "10" @default.
- W192769413 countsByYear W1927694132012 @default.
- W192769413 countsByYear W1927694132020 @default.
- W192769413 crossrefType "journal-article" @default.
- W192769413 hasAuthorship W192769413A5041255852 @default.
- W192769413 hasAuthorship W192769413A5052017127 @default.
- W192769413 hasAuthorship W192769413A5057792641 @default.
- W192769413 hasAuthorship W192769413A5082799023 @default.
- W192769413 hasConcept C126322002 @default.
- W192769413 hasConcept C141071460 @default.
- W192769413 hasConcept C2776021129 @default.
- W192769413 hasConcept C2777514703 @default.
- W192769413 hasConcept C2778478555 @default.
- W192769413 hasConcept C2779631663 @default.
- W192769413 hasConcept C42219234 @default.
- W192769413 hasConcept C4937899 @default.
- W192769413 hasConcept C501593827 @default.
- W192769413 hasConcept C64778159 @default.
- W192769413 hasConcept C71924100 @default.
- W192769413 hasConcept C86803240 @default.
- W192769413 hasConcept C89423630 @default.
- W192769413 hasConcept C94665300 @default.
- W192769413 hasConceptScore W192769413C126322002 @default.
- W192769413 hasConceptScore W192769413C141071460 @default.
- W192769413 hasConceptScore W192769413C2776021129 @default.
- W192769413 hasConceptScore W192769413C2777514703 @default.
- W192769413 hasConceptScore W192769413C2778478555 @default.
- W192769413 hasConceptScore W192769413C2779631663 @default.
- W192769413 hasConceptScore W192769413C42219234 @default.
- W192769413 hasConceptScore W192769413C4937899 @default.
- W192769413 hasConceptScore W192769413C501593827 @default.
- W192769413 hasConceptScore W192769413C64778159 @default.
- W192769413 hasConceptScore W192769413C71924100 @default.
- W192769413 hasConceptScore W192769413C86803240 @default.
- W192769413 hasConceptScore W192769413C89423630 @default.
- W192769413 hasConceptScore W192769413C94665300 @default.
- W192769413 hasIssue "7" @default.
- W192769413 hasLocation W1927694131 @default.
- W192769413 hasLocation W1927694132 @default.
- W192769413 hasOpenAccess W192769413 @default.
- W192769413 hasPrimaryLocation W1927694131 @default.
- W192769413 hasRelatedWork W192769413 @default.
- W192769413 hasRelatedWork W2065165033 @default.
- W192769413 hasRelatedWork W2341279676 @default.
- W192769413 hasRelatedWork W2372732063 @default.
- W192769413 hasRelatedWork W2382555250 @default.
- W192769413 hasRelatedWork W2394459837 @default.
- W192769413 hasRelatedWork W2415366134 @default.
- W192769413 hasRelatedWork W2469363096 @default.
- W192769413 hasRelatedWork W2978292717 @default.
- W192769413 hasRelatedWork W4282548198 @default.
- W192769413 hasVolume "18" @default.
- W192769413 isParatext "false" @default.
- W192769413 isRetracted "false" @default.
- W192769413 magId "192769413" @default.
- W192769413 workType "article" @default.